Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Neurology
•
Neuromuscular
Do patients on eculizumab or ravulizumab require repeat vaccination against meningococcal infection after a certain interval?
Answer from: at Academic Institution
Yes, CDC recommends a booster Men B vaccine 1 year after completion of series and then every 2-3 years thereafter, and booster Men C every 5 years.
Sign in or Register to read more
16983
Related Questions
When do you test for myasthenia antibodies beyond AChR and MuSK?
How do you track objective clinical response to treatment in CIDP?
When and how do you deviate from efgartigimod (Vyvgart) dosing from the drug label recommendation of weekly infusions for four weeks in patients with myasthenia gravis?
To what extent do you incorporate electrodiagnostic testing and ultrasonography in your clinical practice for evaluating suspected cases of meralgia paresthetica?
How do you identify patients with false positive AcHR antibodies?
When do you consider spinal cord stimulator for patients with neuropathic pain?
How do you approach patients with positive LRP4 antibodies without clinical findings of myasthenia gravis?
Do you utilize phrenic nerve EMG in patients with diaphragmatic issues?
Do you choose an antibiotic with CSF penetration, such as nafcillin over cefazolin, in the setting of MSSA endocarditis with septic emboli to the brain (assuming no concomitant meningitis or brain abscess)?
How do you reconcile the benefits of high glycemic load to slow ALS disease progression with previous data on the increased risk for ALS associated with diabetes mellitus?